论文部分内容阅读
目的观察曲妥珠单抗(赫赛汀)联合多西紫杉醇(多帕菲)治疗HER-2过表达乳腺癌患者的阶段性疗效。方法 52例入选患者随机分为观察组(26例)和对照组(26例),观察组患者化疗第一天采用曲妥珠单抗治疗,以后每三周用药一次,用药8~10个周期,第二天联合用多西紫杉醇(多帕菲)化疗,连续用药4个周期。对照组单纯采用多西紫杉醇治疗,连续用药4个周期。结果观察二组患者完成治疗后,KPS评分,观察组高于对照组,二者差异具有统计学意义(P<0.05)。观察组总有效率(76.9%)高于对照组(53.8%),二组差异具有统计学意义(P<0.05)。结论曲妥珠单抗(赫赛汀)联合多西紫杉醇(多帕菲)治疗HER-2过表达乳腺癌患者,疗效较好,静脉滴注曲妥珠单抗时会发生轻度不良反应,对症处理后可缓解。
Objective To observe the staged efficacy of trastuzumab (Herceptin) in combination with docetaxel for HER-2 overexpression in breast cancer patients. Methods Fifty-two patients were randomly divided into observation group (n = 26) and control group (n = 26). Patients in observation group were treated with trastuzumab on the first day of chemotherapy and were treated every three weeks for 8-10 cycles , The next day combined with docetaxel (docetaxel) chemotherapy, continuous medication 4 cycles. The control group was treated with docetaxel alone for 4 cycles. Results After the two groups of patients were treated, the KPS score was higher in the observation group than in the control group, and the difference was statistically significant (P <0.05). The total effective rate (76.9%) in the observation group was higher than that in the control group (53.8%), the difference between the two groups was statistically significant (P <0.05). Conclusions Trastuzumab (Herceptin) combined with docetaxel (docetaxel) in the treatment of HER-2 overexpression breast cancer patients, the effect is good, mild adverse reactions occur when intravenous trastuzumab, After symptomatic treatment can be alleviated.